<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Major side effects and safety of calcium channel blockers</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Major side effects and safety of calcium channel blockers</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Major side effects and safety of calcium channel blockers</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Bloch, MD, FACP, FASH, FSVM, FNLA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan Basile, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Calcium channel blockers are widely used in the treatment of hypertension, angina pectoris, cardiac arrhythmias, and other disorders. The longer-acting preparations have been prescribed with increasing frequency. According to recommendations from the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the prevention, detection, evaluation, and treatment of high blood pressure, calcium channel blockers are a recommended choice for initial management of hypertension, either as monotherapy or as part of antihypertensive combination therapy. There are robust data suggesting that their use reduces the risk of subsequent cardiovascular events [<a href="#rid1">1-3</a>]. In addition, some meta-analyses have suggested that calcium channel blockers may be more effective than other drugs in reducing stroke risk [<a href="#rid4">4-8</a>]. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>A review of the major side effects associated with these agents and the controversy concerning their effect on coronary events, mortality, gastrointestinal bleeding, and the development of cancer are presented here. The management of calcium channel blocker intoxication is presented separately. (See  <a class="medical medical_review" href="/d/html/331.html" rel="external">"Calcium channel blocker poisoning"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TYPES OF CALCIUM CHANNEL BLOCKERS</span><span class="headingEndMark"> — </span>While all approved calcium channel blockers inhibit the L-type calcium channel on cells, they are divided into two major categories based upon their predominant physiologic effects: the dihydropyridines, which are predominantly vasodilators and generally have limited chronotropic and inotropic effects, and the non-dihydropyridines, which are less potent vasodilators and also slow cardiac contractility and conduction [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Dihydropyridines</span><span class="headingEndMark"> — </span>The dihydropyridines, including <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>, <a class="drug drug_general" data-topicid="8585" href="/d/drug information/8585.html" rel="external">isradipine</a>, <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>, <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a>, <a class="drug drug_general" data-topicid="9703" href="/d/drug information/9703.html" rel="external">nisoldipine</a>, lacidipine, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, and <a class="drug drug_general" data-topicid="126414" href="/d/drug information/126414.html" rel="external">levamlodipine</a> are potent vasodilators that have little or no negative effect upon cardiac contractility or conduction. They are typically used to treat hypertension or chronic stable angina. Different agents and preparations have different durations of action. Longer-acting agents are generally safer and are increasingly preferred. These agents are preferred over the non-dihydropyridines for the treatment of hypertension [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Non-dihydropyridines</span><span class="headingEndMark"> — </span>The non-dihydropyridines, including <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, are used in the management of hypertension, chronic stable angina, cardiac arrhythmias, or for proteinuria reduction. They are somewhat less potent vasodilators compared with dihydropyridines, but they have a greater depressive effect on cardiac conduction and contractility. (See  <a class="medical medical_review" href="/d/html/951.html" rel="external">"Calcium channel blockers in the treatment of cardiac arrhythmias"</a> and  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Calcium channel blockers'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">KNOWN SIDE EFFECTS</span></p><p class="headingAnchor" id="H4248664106"><span class="h2">Overview of known adverse effects</span><span class="headingEndMark"> — </span>The potential adverse effects that may be seen with calcium channel blockers vary with the type and dose:</p><p class="bulletIndent1"><span class="glyph">●</span>The dihydropyridines (eg, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>) may lead to headache, lightheadedness, flushing, and dose-dependent peripheral edema in as many as 20 to 30 percent of patients [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major potential adverse effects with the non-dihydropyridines (<a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) are dose-dependent constipation, which may occur in as many as 25 percent of patients [<a href="#rid12">12</a>], as well as bradycardia and worsening cardiac output. Thus, these drugs are relatively contraindicated in patients who are taking beta blockers or who have heart failure with reduced ejection fraction (HFrEF), sick sinus syndrome, and second- or third-degree atrioventricular block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, either dihydropyridines or non-dihydropyridines when used chronically can lead to gingival hyperplasia in some cases.</p><p></p><p>In general, most adverse effects of calcium channel blockers are dose dependent, so a decrease in dose is a possible way to improve tolerability. Patients who do not tolerate dihydropyridines may tolerate a change to non-dihydropyridines and vice versa. Non-dihydropyridines and, to a lesser extent, dihydropyridines are metabolized through the cytochrome P450 (CYP) 3A4 system (like some statins, azoles, protease inhibitors, and other drugs), and, as such, they should be used with caution in patients who are prescribed other agents that affect this metabolic pathway or who consume large amounts of grapefruit juice.</p><p class="headingAnchor" id="H6"><span class="h2">Edema</span><span class="headingEndMark"> — </span>The peripheral edema associated with calcium channel blockers is related to redistribution of fluid from the vascular space into the interstitium. In theory, increased calcium channel blocker-mediated vasodilation leads to increased pressure and subsequent arteriolar permeability in the transcapillary circulation [<a href="#rid13">13</a>]. In one study of 12 healthy subjects, for example, a single dose of <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> increased the foot volume despite also increasing sodium excretion [<a href="#rid14">14</a>]. The risk of edema is more common with dihydropyridines than with non-dihydropyridines and appears to be dose dependent. Risk of dihydropyridine-associated edema is two to three times higher with higher than with lower doses of <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> [<a href="#rid15">15</a>].</p><p>Calcium channel blocker-mediated edema may prompt clinicians to prescribe diuretics, especially loop diuretics, which increase polypharmacy and may cause harm in patients without hypervolemia [<a href="#rid16">16</a>]. However, since calcium channel blocker-mediated edema is not the result of increased plasma volume, it tends not to improve with diuretic therapy [<a href="#rid14">14</a>]. Conversely, addition of an inhibitor of the renin-angiotensin system (RAS), either an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), or a direct renin inhibitor can significantly reduce the incidence and severity of edema caused by calcium channel blockers [<a href="#rid17">17-19</a>]. This effect is probably related to ACE inhibitor- or ARB-mediated venodilation that helps to reduce transcapillary pressure.</p><p>As such, edema caused by dihydropyridine calcium channel blockers can be treated by any combination of the following: reduction in dose, switch to a non-dihydropyridine agent, and/or addition of a RAS-blocking agent.</p><p class="headingAnchor" id="H7"><span class="h2">Effects on cardiac function</span><span class="headingEndMark"> — </span>The non-dihydropyridine calcium channel blockers, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, can diminish cardiac contractility and slow cardiac conduction [<a href="#rid12">12</a>]. As a result, these drugs are relatively contraindicated in patients who are taking beta blockers or who have HFrEF, sick sinus syndrome, and second- or third-degree atrioventricular block.</p><p class="headingAnchor" id="H8"><span class="h3">Use in heart failure and coronary artery disease</span><span class="headingEndMark"> — </span>Due to their negative inotropic effects, non-dihydropyridine calcium channel blockers should not be used in patients with HFrEF. (See  <a class="medical medical_review" href="/d/html/3455.html" rel="external">"Calcium channel blockers in heart failure with reduced ejection fraction"</a>.)</p><p>However, it does appear that both types of calcium channel blockers can be used safely in patients who have heart failure with preserved ejection fraction (HFpEF), and they may also be used in patients with myocardial infarction (MI) and chronic stable angina. (See  <a class="medical medical_review" href="/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Calcium channel blockers'</a>.)</p><p>Use of short-acting dihydropyridines has been demonstrated to cause reflex tachycardia and an increase in sympathetic tone, which may lead to poor outcomes in patients with heart failure and coronary disease. As such, these short-acting agents are generally no longer commercially available (or, if available, seldom used). However, the long-acting dihydropyridines (such as <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, extended-release <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>, and <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>) appear to be safe when used in patients with coronary artery disease or heart failure [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H93142750"><span class="h1">PROPOSED BUT UNPROVEN SERIOUS ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Several serious adverse effects have been ascribed to calcium channel blockers, although the data supporting these links are weak and inconclusive:</p><p class="bulletIndent1"><span class="glyph">●</span>An increased mortality after acute myocardial infarction (MI) with short-acting but <strong>not</strong> long-acting agents</p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk for acute MI in hypertensive patients taking short-acting but <strong>not</strong> long-acting agents</p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk of cancer, particularly breast cancer, although this was not seen in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [<a href="#rid21">21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk of gastrointestinal hemorrhage</p><p></p><p>Short-acting dihydropyridine calcium channel blockers should generally be avoided. However, long-acting agents, such as <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a> or <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, appear to be safe and effective in treating hypertension and reducing cardiovascular events, including MI.</p><p class="headingAnchor" id="H10"><span class="h2">Possible increased mortality after acute myocardial infarction</span><span class="headingEndMark"> — </span>Large doses of short-acting <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> may increase mortality in patients in the immediate post-MI period [<a href="#rid22">22</a>]. The potential for harm from the profound hypotension and sympathetic activation induced by such large doses of short-acting nifedipine is incontrovertible in these hemodynamically vulnerable patients (<a class="graphic graphic_table graphicRef52312" href="/d/graphic/52312.html" rel="external">table 1</a>). Thus, there is no compelling reason to use short-acting calcium channel blockers in such patients.</p><p class="headingAnchor" id="H11"><span class="h3">Possible increased risk for acute myocardial infarction with short-acting agents</span><span class="headingEndMark"> — </span>A highly publicized observational study from 1995 suggested that calcium channel blockers increased the risk for an acute MI [<a href="#rid23">23</a>]. Further review suggests that this risk, if it exists, is pertinent only to short-acting dihydropyridines. Multiple randomized, controlled trials involving thousands of hypertensive patients have since found no evidence of increased coronary risk from long-acting calcium channel blockers that do not share the possible harmful cardiovascular effects of the short-acting preparations (<a class="graphic graphic_table graphicRef52312" href="/d/graphic/52312.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H18674251"><span class="h3">Possible increased cancer risk</span><span class="headingEndMark"> — </span>Although some observational studies suggest an association, the balance of data does <strong>not</strong> support an increased cancer risk among those exposed to calcium channel blockers.</p><p>Several observational studies have found an association between calcium channel blockers and an increased risk of cancer [<a href="#rid24">24-26</a>], particularly breast cancer [<a href="#rid24">24</a>]. In a retrospective, case-control study, for example, current and prior use of antihypertensive medications were ascertained from 1907 women diagnosed with breast cancer plus 856 women without breast cancer who were randomly selected from the phone book [<a href="#rid24">24</a>]. Although the use of calcium channel blockers for less than 10 years was not associated with cancer, a subgroup analysis revealed an increased risk of breast cancer among women who used calcium channel blockers for 10 or more years. However, because of the methodologic limitations of this and other observational studies, a causal link between calcium channel blockers and cancer cannot be established based upon these data.</p><p>By contrast, a large meta-analysis of antihypertensive medication trials that included more than 300,000 individuals found that calcium channel blockers did not increase the incidence of cancer (odds ratio [OR] 1.05, 95% CI 0.96-1.13) or cancer-related mortality (OR 0.96, 95% CI 0.82-1.11), although the risk of breast cancer, per se, was not analyzed [<a href="#rid27">27</a>]. Additionally, a large, population-based study in the United Kingdom demonstrated no increased risk of overall cancer or breast cancer among people exposed to calcium channel blockers, regardless of duration of exposure [<a href="#rid28">28</a>]. Another large cohort found a lower risk of gastric cancer among those treated with calcium channel blockers [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Possible increased gastrointestinal bleeding risk in older adults</span><span class="headingEndMark"> — </span>Previous observational studies have suggested a possible increased risk of gastrointestinal bleeding with calcium channel blocker use, particularly among older adults. However, these data have not been confirmed in most subsequent reports, including in large, randomized trials (ALLHAT) and meta-analyses.</p><p>As an example, in a retrospective analysis of approximately 1000 hypertensive patients among a total of 8000 older adult individuals screened as part of a three-community epidemiologic study, a higher rate of gastrointestinal hemorrhage was observed in those taking short-acting <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, but not <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> [<a href="#rid30">30</a>]. However, a more complete analysis of available data, including those from clinical trials with <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> (including the ALLHAT), suggested that this association was uncertain or unlikely [<a href="#rid31">31</a>]. In addition, a systematic review and meta-analysis of 17 clinical trials demonstrated, at most, a marginal association between calcium channel use and gastrointestinal bleeding, which did not appear to be of important clinical significance [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8527151"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16828.html" rel="external">"Patient education: Side effects from medicines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>All approved calcium channel blockers inhibit the L-type calcium channel on cells but are divided into two major categories based upon their predominant physiologic effects: the dihydropyridines, which are predominantly vasodilators and have less chronotropic and inotropic effects, and the non-dihydropyridines, which are less potent vasodilators and also slow cardiac contractility and conduction. (See <a class="local">'Dihydropyridines'</a> above and <a class="local">'Non-dihydropyridines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The potentially adverse effects that may be seen with calcium channel blockers vary with the type and dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The dihydropyridines (eg, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>) may lead to headache, lightheadedness, flushing, and dose-dependent peripheral edema in as many as 20 to 30 percent of patients. Edema is related to redistribution of fluid from the vascular space into the interstitium and can be treated by any combination of the following: reduction in dose, switch to a non-dihydropyridine agent, or addition of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). (See <a class="local">'Edema'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The major potential adverse effects with the non-dihydropyridines (<a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) are constipation, which may occur in as many as 25 percent of patients, as well as bradycardia and worsening cardiac output. Due to their negative chronotropic and inotropic effects, non-dihydropyridine calcium channel blockers should not be used in patients taking beta blockers or in those with heart failure and reduced ejection fraction (HFrEF), sick sinus syndrome, or second- or third-degree atrioventricular block. (See <a class="local">'Effects on cardiac function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, chronic use of either dihydropyridines or non-dihydropyridines can lead to gingival hyperplasia in some cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several serious adverse effects have been ascribed to calcium channel blockers, although the data supporting these links are weak and inconclusive: an increased mortality after acute myocardial infarction (MI) with short-acting but <strong>not</strong> long-acting agents; an increased risk for acute MI in hypertensive patients taking short-acting but <strong>not</strong> long-acting agents; an increased risk of cancer, particularly breast cancer; and an increased risk of gastrointestinal hemorrhage. Stronger data indicate that calcium channel blockers <strong>do not</strong> increase the risk of cancer or gastrointestinal hemorrhage. Thus, short-acting dihydropyridine calcium channel blockers should generally be avoided. However, long-acting agents, such as <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> gastrointestinal therapeutic system (GITS) or <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, appear to be safe and effective in treating hypertension and reducing cardiovascular events, including MI but especially stroke. (See <a class="local">'Proposed but unproven serious adverse effects'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.</a></li><li><a class="nounderline abstract_t">Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.</a></li><li><a class="nounderline abstract_t">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.</a></li><li><a class="nounderline abstract_t">Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805.</a></li><li><a class="nounderline abstract_t">ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.</a></li><li><a class="nounderline abstract_t">Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:641.</a></li><li><a class="nounderline abstract_t">Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008; 73:795.</a></li><li><a class="nounderline abstract_t">Triggle DJ. Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev Technol 2003; 1:719.</a></li><li><a class="nounderline abstract_t">Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001; 15:455.</a></li><li><a class="nounderline abstract_t">Krakoff LR. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH Trial. J Cardiovasc Pharmacol 1993; 21 Suppl 2:S14.</a></li><li><a class="nounderline abstract_t">Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341:1447.</a></li><li><a class="nounderline abstract_t">Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens 2011; 29:1270.</a></li><li><a class="nounderline abstract_t">van Hamersvelt HW, Kloke HJ, de Jong DJ, et al. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens 1996; 14:1041.</a></li><li><a class="nounderline abstract_t">Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 2000; 35:621.</a></li><li><a class="nounderline abstract_t">Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA Intern Med 2020; 180:643.</a></li><li><a class="nounderline abstract_t">Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124:128.</a></li><li><a class="nounderline abstract_t">Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963.</a></li><li><a class="nounderline abstract_t">Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377:312.</a></li><li><a class="nounderline abstract_t">de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J 2000; 139:185.</a></li><li><a class="nounderline abstract_t">Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48:374.</a></li><li><a class="nounderline abstract_t">Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.</a></li><li><a class="nounderline abstract_t">Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620.</a></li><li><a class="nounderline abstract_t">Li CI, Daling JR, Tang MT, et al. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013; 173:1629.</a></li><li><a class="nounderline abstract_t">Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9:695.</a></li><li><a class="nounderline abstract_t">Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348:493.</a></li><li><a class="nounderline abstract_t">Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65.</a></li><li><a class="nounderline abstract_t">Grimaldi-Bensouda L, Klungel O, Kurz X, et al. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open 2016; 6:e009147.</a></li><li><a class="nounderline abstract_t">Li B, Cheung KS, Wong IY, et al. Calcium channel blockers are associated with lower gastric cancer risk: A territory-wide study with propensity score analysis. Int J Cancer 2021; 148:2148.</a></li><li><a class="nounderline abstract_t">Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061.</a></li><li><a class="nounderline abstract_t">Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 2001; 161:1145.</a></li><li><a class="nounderline abstract_t">He Y, Chan EW, Leung WK, et al. Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding. Aliment Pharmacol Ther 2015; 41:1246.</a></li></ol></div><div id="topicVersionRevision">Topic 3832 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480116" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817082" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657064" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479763" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716708" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340349" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Calcium antagonists: Do they equally protect against kidney injury?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090244" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drug targets in the voltage-gated calcium channel family: why some are and some are not.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464254" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692145" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547409" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Calcium-antagonist drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21558959" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8884561" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679507" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Amlodipine, enalapril, and dependent leg edema in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32091538" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21295192" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587165" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236483" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650289" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864749" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7648682" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637142" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The risk of myocardial infarction associated with antihypertensive drug therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921840" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806983" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Do calcium channel blockers increase the risk of cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Calcium-channel blockade and incidence of cancer in aged populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123111" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33152125" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Calcium channel blockers are associated with lower gastric cancer risk: A territory-wide study with propensity score analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602055" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343438" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25898902" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
